Medical Care Technologies Inc.
MDCENext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MDCE. That does not mean none is planned.
Get an email about MDCE's next catalysts
Track Medical Care Technologies (MDCE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
hydrocortisone sodium succinate
Shock, Septic
Clarithromycin Extended Release
Mycobacterium Ulcerans Infection
Low-dose PPI (Rabeprazole sodium)
Cardio-cerebrovascular Disease
Ferric carboxymaltose
Iron-deficiency
Intravenous Magnesium Sulfate
Sickle Cell Disease
Antispike gel, 100 g in a flask, produced by UNITEHPROM BSU, Republic of Belarus
Abdominal Adhesions
CT-011
Multiple Myeloma
Alpha, gamma, beta, and delta (mixed) tocopherols
End-stage Renal Disease
low-dose sucroferric oxyhydroxide
Endstage Renal Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
hydrocortisone sodium succinate | Phase 3 | Shock, Septic | - | - |
Clarithromycin Extended Release | Phase 3 | Mycobacterium Ulcerans Infection | - | - |
Low-dose PPI (Rabeprazole sodium) | Phase 3 | Cardio-cerebrovascular Disease | - | - |
Ferric carboxymaltose | Phase 3 | Iron-deficiency | - | - |
Intravenous Magnesium Sulfate | Phase 3 | Sickle Cell Disease | - | - |
Antispike gel, 100 g in a flask, produced by UNITEHPROM BSU, Republic of Belarus | Phase 2 | Abdominal Adhesions | - | - |
CT-011 | Phase 2 | Multiple Myeloma | - | - |
Alpha, gamma, beta, and delta (mixed) tocopherols | Phase 2 | End-stage Renal Disease | - | - |
low-dose sucroferric oxyhydroxide | Phase 2 | Endstage Renal Disease | - | - |
lung cancer diagnosis
1 drug in this indication
cardiac arrhythmia
1 drug in this indication
Atopic dermatitis
1 drug in this indication
Vaginismus / painful penetration
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Medical Care Technologies Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in Medical Care Technologies Inc.'s (MDCE) pipeline across Phase 3, Phase 2. Its lead program is Clarithromycin Extended Release (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Medical Care Technologies Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Medical Care Technologies Inc. (MDCE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MDCE biotech catalysts?→
Add MDCE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Medical Care Technologies Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.